Avantor price to free cash flow AVTR

Market value divided by free cash flow over the last twelve months, since 2020.

Today, Oct 23, 2026: 25.7×
6-year median: 20.7×
Against its 6-year history: 90th; percentile: 0 is its lowest day, 100 its highest
6-year range: 10.2× to 29.6×
Peer median: 27.2×

Avantor's price to free cash flow is 25.7× as of Oct 23, 2026.

That is above its 6-year median of 20.7×, higher than on 90% of days in the last 6 years.

Over that time it ranged from 10.2× in Mar 2026 to 29.6× in Dec 2021.

The median for 10 diagnostics and research stocks of a similar size is 27.2×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	25.7×	10.2×	25.7×
2025	14.9×	12.3×	20.3×
2024	19.5×	18.9×	26.6×
2023	22.2×	16.9×	23.8×
2022	17.8×	16.2×	26.5×
2021	29.6×	18.3×	29.6×
2020	24.8×	20.1×	24.9×

Against its peers

Companies in Medical - Diagnostics & Research nearest Avantor's size, closest first, today.

Company	Price to free cash flow
AVTRAvantor	25.7×
BIOBio-Rad Laboratories	28.0×
CAICaris Life Sciences	73.0×
RVTYRevvity	31.7×
MEDPMedpace	26.4×
LNTHLantheus	16.8×
LHLabcorp	23.1×
DGXQuest Diagnostics	19.8×
BLLNBillionToOne	153×
MTDMettler-Toledo International	38.7×
VCYTVeracyte	23.2×
Peer median	27.2×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Avantor

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.